Welcome to our dedicated page for ENDP news (Ticker: ENDP), a resource for investors and traders seeking the latest updates and insights on ENDP stock.
Endo International plc (OTC: ENDPQ) maintains this comprehensive news hub to keep stakeholders informed about developments in specialty pharmaceuticals. Our curated collection features official press releases and verified updates directly impacting the company's operations and therapeutic innovations.
Visitors will find timely information on clinical trial progress, including collagenase clostridium histolyticum (CCH) research for plantar fibromatosis, regulatory milestones, strategic partnerships, and financial restructuring updates. The resource prioritizes verified updates across Endo's core therapeutic areas: pain management, urology, endocrinology, and oncology.
This centralized news source enables efficient tracking of both scientific advancements and organizational developments. All content undergoes rigorous verification to ensure accuracy and relevance for investment research and industry analysis.
Bookmark this page for direct access to Endo's latest announcements. For additional corporate information, visit the official Endo International website.
Endo International plc (NASDAQ: ENDP) has announced a $63 million settlement to resolve all government-related opioid claims in Texas. This agreement occurs without an admission of wrongdoing and aims to conclude litigation involving Endo's subsidiaries, including cases set for trial in 2022. The settlement is contingent on certain conditions, and while it resolves specific claims, Endo continues to face litigation related to other opioid claims. The company is also exploring strategic alternatives amid ongoing challenges in the opioid litigation landscape.
Endo International plc (NASDAQ: ENDP) announced a partnership with SK Biopharmaceuticals to develop and commercialize cenobamate in Canada. Paladin Labs, a subsidiary of Endo, will handle the commercial activities for this anti-seizure medication. Cenobamate, which is approved in the U.S. and Europe for partial-onset seizures, is under investigation for broader applications. The collaboration aims to address unmet needs in epilepsy treatment, potentially expanding Endo's neurology portfolio and improving market presence in the Canadian pharmaceutical landscape.
Endo International plc (NASDAQ: ENDP) announced a favorable ruling from a California trial court, concluding that it and its subsidiaries are not liable in a public nuisance case regarding opioid medications. The case was filed in 2014 by California counties, and the court found that plaintiffs failed to prove misleading marketing or a causal link between Endo's marketing and opioid abuse. Endo's leadership emphasizes their commitment to addressing the opioid crisis through collaboration.
Endo International plc (NASDAQ:ENDP) presented new data on Qwo® at the American Society for Dermatologic Surgery (ASDS) annual meeting held virtually from November 19-21, 2021. The data focused on the safety and efficacy of Qwo® for treating moderate to severe cellulite in adult women's buttocks. Key findings included analyses of Qwo® in women with skin of color and real-world effectiveness data. Qwo®, approved by the FDA since July 2020, aims to address unmet needs in aesthetic treatments.
Endo International plc (NASDAQ: ENDP) has announced the launch of its generic calcitonin salmon injection following FDA approval. This product targets conditions such as hypercalcemia, postmenopausal osteoporosis, and Paget's disease of bone. The U.S. market for calcitonin salmon injection was approximately $170M in the past year. Manufactured in Rochester, MI, this injectable is positioned as a cost-effective alternative to Viatris' MIACALCIN®. The launch may enhance Endo's revenue, providing healthcare professionals with a new high-quality treatment option.
Endo International announced a cooperative agreement through its subsidiary Par Sterile Products to expand fill-finish manufacturing at its Rochester, MI facility. This initiative will enhance production capacity for mRNA and adenovirus vaccines, supported by approximately $90 million in funding from the U.S. government, part of a total project cost of $120 million. The agreement aligns with the Defense Production Act, aiming to strengthen domestic production of essential medicines.
Endo International plc (NASDAQ: ENDP) has announced its Par Sterile Products business will supply VASOSTRICT®, a vasopressin injection, to healthcare providers through Premier's Premier ProRx® program. This collaboration aims to ensure a reliable supply of this critical care medication, particularly for COVID-19 cases. Scott Sims, Senior VP and General Manager of Sterile Injectables, highlighted the partnership as a response to industry drug shortages.
Endo International reported Q3 2021 financial results, revealing total revenues of $772 million, a 22% increase year-over-year, driven by growth in Sterile Injectables and Generic Pharmaceuticals. The reported loss from continuing operations improved to $49 million, a 29% decrease from last year. Adjusted income surged 55% to $189 million, with adjusted diluted net income per share rising 54% to $0.80. Endo raised its full-year guidance for revenues and adjusted EBITDA, reflecting a positive outlook amidst ongoing COVID-19 uncertainties.
Endo International plc (NASDAQ: ENDP) has received a tentative ruling from a California state court, stating that the company and its subsidiaries are not liable in one of the first public nuisance cases against opioid manufacturers. The ruling was issued on November 1, 2021, following a trial that lasted several months. The plaintiffs included Orange and Santa Clara Counties, who filed the case in 2014. Endo is required to submit a proposed decision and judgment consistent with the ruling within 30 days.
Endo International plc (NASDAQ: ENDP) has launched its first television advertisement for XIAFLEX, the only FDA-approved nonsurgical treatment for Peyronie's disease (PD), featuring a bent carrot as a symbol. The campaign aims to raise awareness and encourage men experiencing symptoms to consult a healthcare professional. The commercial will air during prime time on major networks and streaming services starting October 2021. According to market research, it can take men up to seven years to seek treatment for PD, often due to stigma and misdiagnosis.
